Brokers Offer Predictions for Nuvalent, Inc.’s FY2025 Earnings (NASDAQ:NUVL)

Nuvalent, Inc. (NASDAQ:NUVL) – Investment analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Nuvalent in a research note issued on Sunday, September 15th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($5.32) per share for the year, down from their prior estimate of ($5.26). The consensus estimate for Nuvalent’s current full-year earnings is ($3.55) per share. Leerink Partnrs also issued estimates for Nuvalent’s FY2026 earnings at ($5.87) EPS and FY2027 earnings at ($4.61) EPS.

NUVL has been the topic of several other reports. Guggenheim boosted their price target on Nuvalent from $99.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday. JPMorgan Chase & Co. boosted their price target on Nuvalent from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Barclays began coverage on Nuvalent in a research report on Thursday, August 29th. They set an “overweight” rating and a $100.00 price target on the stock. Stifel Nicolaus upped their target price on Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday. Finally, The Goldman Sachs Group raised Nuvalent to a “strong sell” rating in a research report on Monday. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $111.00.

Nuvalent Stock Performance

Shares of NASDAQ:NUVL opened at $103.25 on Wednesday. The stock has a 50-day simple moving average of $81.25 and a 200-day simple moving average of $76.16. The stock has a market capitalization of $6.67 billion, a P/E ratio of -42.84 and a beta of 1.28. Nuvalent has a 1 year low of $41.16 and a 1 year high of $113.51.

Nuvalent (NASDAQ:NUVL) last issued its earnings results on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). During the same period last year, the firm posted ($0.51) earnings per share.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in NUVL. Darwin Global Management Ltd. grew its stake in Nuvalent by 2,390.5% during the 1st quarter. Darwin Global Management Ltd. now owns 1,436,964 shares of the company’s stock worth $107,902,000 after buying an additional 1,379,266 shares during the last quarter. Vanguard Group Inc. grew its stake in Nuvalent by 56.5% during the 4th quarter. Vanguard Group Inc. now owns 3,339,850 shares of the company’s stock worth $245,780,000 after buying an additional 1,205,668 shares during the last quarter. Commodore Capital LP grew its stake in Nuvalent by 60.6% during the 4th quarter. Commodore Capital LP now owns 1,331,037 shares of the company’s stock worth $97,951,000 after buying an additional 502,259 shares during the last quarter. Perceptive Advisors LLC grew its stake in shares of Nuvalent by 18.5% in the fourth quarter. Perceptive Advisors LLC now owns 2,917,991 shares of the company’s stock worth $214,735,000 after purchasing an additional 454,540 shares in the last quarter. Finally, Samlyn Capital LLC bought a new position in shares of Nuvalent in the second quarter worth $17,397,000. 97.26% of the stock is currently owned by institutional investors.

Insider Activity at Nuvalent

In related news, Director Matthew Shair sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $80.22, for a total transaction of $160,440.00. Following the sale, the director now directly owns 232,522 shares of the company’s stock, valued at approximately $18,652,914.84. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Matthew Shair sold 2,000 shares of the company’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $80.22, for a total transaction of $160,440.00. Following the completion of the transaction, the director now directly owns 232,522 shares in the company, valued at approximately $18,652,914.84. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Alexandra Balcom sold 10,000 shares of the company’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $75.43, for a total value of $754,300.00. Following the transaction, the chief financial officer now owns 33,300 shares of the company’s stock, valued at $2,511,819. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 117,629 shares of company stock valued at $10,062,198. Corporate insiders own 12.52% of the company’s stock.

Nuvalent Company Profile

Nuvalent, Inc, a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial.